Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for glucocorticoid excess. It was founded to spare patients from the ravages of steroids. Leveraging underappreciated scientific insights in glucocorticoid biology, the company is working to provide better treatment options for severe hypercortisolism conditions and revolutionize the treatment of autoimmune and inflammatory disorders. Its lead product, SPI-62, is an orally administered small molecule drug and represents a novel therapeutic approach designed to target the source of active intracellular corticosteroids in key tissues.